Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin

Annals of Pharmacotherapy

Volumn 31, Issue 7-8, 1997, Pages 859-863

  Grunden, John W ^a,b,c   Fisher, Kenneth A ^d  

^a FERRIS STATE UNIVERSITY   (United States)

^b BRONSON METHODIST HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Azithromycin; Clarithromycin; Lovastatin; Rhabdomyolysis

Indexed keywords

BENZTHIAZIDE; CLARITHROMYCIN; COLCHICINE; CREATINE KINASE; DILTIAZEM; FAMOTIDINE; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; PREDNISONE; PROBENECID; SALBUTAMOL; THYROTROPIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HEADACHE; HUMAN; HYDRATION; MALE; MYALGIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; VERTIGO;

EID: 0030878912     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100710     Document Type: Article

References (33)

1. Top 200 drugs of 1995. Pharm Times 1996;62:27-36.
2. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
3. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
4. Hoeg JM, Brewer HB Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987; 258:3532-6.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
6. Walker JF. Worldwide experience with simvastatin/lovastatin. Eur Heart J 1992;13(suppl B):21-2.
7. Package insert. Mevacor (lovastatin). West Point, PA: Merck & Co., Inc., 1994.
8. Fernandez-Zatarain G, Navarro V, Garcia H, Villatoro J, Calvo C. Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron 1994;66:483-4.
9. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992;26:190-2.
10. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71-5.
11. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-8.
12. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988;318:48.
13. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988;109:682-3.
14. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
15. Marinella MA. More on lovastatin. West J Med 1994;162:176-7.
16. Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine 1982;61:141-52.
17. Curry SC, Chang D, Connor D. Drug-and toxin-induced rhabdomyolysis. Ann Emerg Med 1989;18:1068-84.
18. Pina EM, Mehlman CT. Rhabdomyolysis. A primer for the orthopaedist. Orthop Rev 1994;23:28-32.
19. Arrington ED, Miller MD. Skeletal muscle injuries. Orthop Clin North Am 1995;26:411-22.
20. Prendergast BD, George CF. Drug-induced rhabdomyolysis: mechanisms and management. Postgrad Med J 1993;69:333-6.
21. Reha WC, Mangano FA, Zeman RK, Pahira JJ. Rhabdomyolysis: need for high index of suspicion. Urology 1989;34:292-6.
22. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991;41:1159-60.
23. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990;87:8931-4.
24. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990;36:2145-7.
25. Goldman JA. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989;32:358-9.
26. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-8.
27. Hansten PD, Horn JR, eds. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc., 1995.
28. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992; 26:46-55.
29. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin. New macrolide antibiotics. Clin Pharm 1992;11:137-52.
30. Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992;26:1099-108.
31. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991;35: 1186-90.
32. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, et al. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. Eur Heart J 1992;13:2-6.
33. Tandan R, Bradley WG. Dermatomyositis and polymyositis. In: Isselbacher KJ, Braunwald E, Wilson JD, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, Inc., 1994:2379-83.